English
Back
Open Account
Around 80% of IPOs are expected to rise on their debut in 2026! Xiantong Pharmaceutical is set to li
牛牛新股君
joined discussion · Nov 11 07:38

IPO Pricing | New Lotus listed today, receiving over 2,100x subscription. The offer price was set at HK$40.2 per share, with a grey market profit of HK$517.5 per lot.

Futu News, November 11:$NEAUTUS (02206.HK)$Announced allotment results: the offer price was set at HK$40.2 per share, with a total issuance of 6.5173 million shares. Each lot consists of 50 shares, and the stock officially listed today.
On the previous trading day, New Lotus closed up 25.75% in the grey market at HK$10.15. With a lot size of 50 shares and excluding fees, the profit per lot was HK$517.5.
During the public offering phase, New Lotus saw subscription demand of 2,190.99 times. After reallocation, the final number of shares offered to the public was 651,700, representing approximately 10% of the total offering. A total of approximately 58,843 valid applications were received, with about 12,729 applications accepted. The approximate percentage of shares allocated for one-lot applications relative to the total shares applied for was 2.01%.
Additionally, during the international placement phase, New Lotus received subscriptions of 1.25 times. After reallocation, the final number of internationally placed shares was 5.8655 million, equivalent to 90% of the total offering. Futu has compiled the relevant data in the table below:
Futu News, November 11:$NEAUTUS (02206.HK)$Announced allotment results: the offer price was set at HK$40.2 per share, with a total issuance of 6.5173 million shares. Each lot consists of 50 shares, and the stock officially listed today. In the previous trading session, New Lotus closed up 25.75% in the grey market at HK$10.15. With 50 shares per lot and excluding fees, the profit per lot was HK$517.5. During the public offering phase, New Lotus received 2,190.99x subscription. After reallocation, the final number of shares for the public offering was 651,700, accounting for approximately 10% of the total offering shares. A total of approximately 58,843 valid applications were received, with about 12,729 applications accepted. The approximate percentage of allocated shares for one-lot applicants relative to the total applied shares was 2.01%. Additionally, during the international placement phase, New Lotus received 1.25x subscription. After reallocation, the final number of internationally placed shares was 5.8655 million, equivalent to 90% of the total offering shares. Futu has compiled the relevant data in the table below: Company Overview The company is a major supplier of traditional Chinese medicine (TCM) decoction pieces in China. Based on 2025 revenue from TCM decoction pieces, the company ranks 2nd in China, holding a 0.4% market share in a highly competitive landscape, while the top five market participants collectively hold a 2.7% market share. The company has established and implemented stringent production and quality control standards for TCM...
Futu News, November 11:$NEAUTUS (02206.HK)$Announced allotment results: the offer price was set at HK$40.2 per share, with a total issuance of 6.5173 million shares. Each lot consists of 50 shares, and the stock officially listed today. In the previous trading session, New Lotus closed up 25.75% in the grey market at HK$10.15. With 50 shares per lot and excluding fees, the profit per lot was HK$517.5. During the public offering phase, New Lotus received 2,190.99x subscription. After reallocation, the final number of shares for the public offering was 651,700, accounting for approximately 10% of the total offering shares. A total of approximately 58,843 valid applications were received, with about 12,729 applications accepted. The approximate percentage of allocated shares for one-lot applicants relative to the total applied shares was 2.01%. Additionally, during the international placement phase, New Lotus received 1.25x subscription. After reallocation, the final number of internationally placed shares was 5.8655 million, equivalent to 90% of the total offering shares. Futu has compiled the relevant data in the table below: Company Overview The company is a major supplier of traditional Chinese medicine (TCM) decoction pieces in China. Based on 2025 revenue from TCM decoction pieces, the company ranks 2nd in China, holding a 0.4% market share in a highly competitive landscape, while the top five market participants collectively hold a 2.7% market share. The company has established and implemented stringent production and quality control standards for TCM...
Company Overview
The company is a major supplier of traditional Chinese medicine (TCM) decoction pieces in China. Based on TCM decoction piece revenue in 2025, the company ranks second in China, holding a 0.4% market share in a highly competitive landscape, while the top five market participants collectively hold a 2.7% market share. The company has established and implemented stringent standards for TCM production and quality control, integrating digital technology into its production and quality control processes.
The company serves a wide range of institutional and retail clients—including hospitals and medical institutions, medical trading companies, pharmacies, pharmaceutical companies, and more recently, individual consumers—by providing traditional herbal preparations, health products, and health management services. Its business covers most provinces in mainland China, as well as Hong Kong, Taiwan, and selected overseas markets such as Vietnam and Malaysia.
Financial Overview
The company's revenue increased from RMB 1,145.6 million in 2023 to RMB 1,334.7 million in 2025, with gross profit rising from RMB 212.0 million to RMB 253.2 million in the same year. Furthermore, the company's revenue grew from RMB 382.8 million in the four months ended April 30, 2025, to RMB 432.2 million in the four months ended April 30, 2026, while gross profit increased from RMB 72.2 million to RMB 94.2 million during the same period.
Futu News, November 11:$NEAUTUS (02206.HK)$Announced allotment results: the offer price was set at HK$40.2 per share, with a total issuance of 6.5173 million shares. Each lot consists of 50 shares, and the stock officially listed today. In the previous trading session, New Lotus closed up 25.75% in the grey market at HK$10.15. With 50 shares per lot and excluding fees, the profit per lot was HK$517.5. During the public offering phase, New Lotus received 2,190.99x subscription. After reallocation, the final number of shares for the public offering was 651,700, accounting for approximately 10% of the total offering shares. A total of approximately 58,843 valid applications were received, with about 12,729 applications accepted. The approximate percentage of allocated shares for one-lot applicants relative to the total applied shares was 2.01%. Additionally, during the international placement phase, New Lotus received 1.25x subscription. After reallocation, the final number of internationally placed shares was 5.8655 million, equivalent to 90% of the total offering shares. Futu has compiled the relevant data in the table below: Company Overview The company is a major supplier of traditional Chinese medicine (TCM) decoction pieces in China. Based on 2025 revenue from TCM decoction pieces, the company ranks 2nd in China, holding a 0.4% market share in a highly competitive landscape, while the top five market participants collectively hold a 2.7% market share. The company has established and implemented stringent production and quality control standards for TCM...
Futu News, November 11:$NEAUTUS (02206.HK)$Announced allotment results: the offer price was set at HK$40.2 per share, with a total issuance of 6.5173 million shares. Each lot consists of 50 shares, and the stock officially listed today. In the previous trading session, New Lotus closed up 25.75% in the grey market at HK$10.15. With 50 shares per lot and excluding fees, the profit per lot was HK$517.5. During the public offering phase, New Lotus received 2,190.99x subscription. After reallocation, the final number of shares for the public offering was 651,700, accounting for approximately 10% of the total offering shares. A total of approximately 58,843 valid applications were received, with about 12,729 applications accepted. The approximate percentage of allocated shares for one-lot applicants relative to the total applied shares was 2.01%. Additionally, during the international placement phase, New Lotus received 1.25x subscription. After reallocation, the final number of internationally placed shares was 5.8655 million, equivalent to 90% of the total offering shares. Futu has compiled the relevant data in the table below: Company Overview The company is a major supplier of traditional Chinese medicine (TCM) decoction pieces in China. Based on 2025 revenue from TCM decoction pieces, the company ranks 2nd in China, holding a 0.4% market share in a highly competitive landscape, while the top five market participants collectively hold a 2.7% market share. The company has established and implemented stringent production and quality control standards for TCM...
Use of Proceeds
Regarding the use of proceeds, New Lotus expects the net proceeds from the global offering to be approximately HK$229 million (based on an offer price of HK$40.2). According to the prospectus, New Lotus intends to use the funds raised from the global offering for the following purposes:
Approximately 33.4% will be used to expand the production capacity of TCM decoction pieces and upgrade the digitalized intelligent production system; approximately 29.0% will be allocated to the Company’s sales and marketing activities, which are expected to commence by the end of 2026 and be completed by the end of 2028; approximately 11.4% will be used for the Company’s consumer-facing business from 2026 to 2028; approximately 10.2% will be utilized to establish overseas sales channels in Vietnam and Malaysia by the end of 2027; approximately 6.0% will be directed toward strategic investments and potential acquisitions, with a focus on the upstream supply chain of TCM; and approximately 10.0% will be reserved for working capital and other general corporate purposes.
The golden season for IPO subscriptions is here! Subscribe to IPOs with Futu: 0% interest, 0 fees, and cash-free subscription. Participate in the campaign now for a chance to waive IPO subscription fees for one year.Try it out now >>
Futu News, November 11:$NEAUTUS (02206.HK)$Announced allotment results: the offer price was set at HK$40.2 per share, with a total issuance of 6.5173 million shares. Each lot consists of 50 shares, and the stock officially listed today. In the previous trading session, New Lotus closed up 25.75% in the grey market at HK$10.15. With 50 shares per lot and excluding fees, the profit per lot was HK$517.5. During the public offering phase, New Lotus received 2,190.99x subscription. After reallocation, the final number of shares for the public offering was 651,700, accounting for approximately 10% of the total offering shares. A total of approximately 58,843 valid applications were received, with about 12,729 applications accepted. The approximate percentage of allocated shares for one-lot applicants relative to the total applied shares was 2.01%. Additionally, during the international placement phase, New Lotus received 1.25x subscription. After reallocation, the final number of internationally placed shares was 5.8655 million, equivalent to 90% of the total offering shares. Futu has compiled the relevant data in the table below: Company Overview The company is a major supplier of traditional Chinese medicine (TCM) decoction pieces in China. Based on 2025 revenue from TCM decoction pieces, the company ranks 2nd in China, holding a 0.4% market share in a highly competitive landscape, while the top five market participants collectively hold a 2.7% market share. The company has established and implemented stringent production and quality control standards for TCM...
Edited by Vincent
Risk Disclaimer: The above content only represents the author's view. It does not represent any position or investment advice of Futu. Futu makes no representation or warranty.Read more
Emm
1
Thumbs Up
3
Lol
1
36K Views
Report
Comments
Write a Comment...
5
12